Business

Several prominent Indian pharmaceutical firms, including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifesciences, maintain substantial export operations to the USA. (AI image) Pharma stocks hit by Trump’s tariffs: Pharmaceutical stocks declined sharply by up to 5% on Friday, September 26, following US President Donald Trump’s declaration of imposing 100% tariffs…

Top stocks to buy (AI image) Stock market recommendations: According to Bajaj Broking Research, the top stock picks for September 26, 2025 are Sagility, and Hindustan Zinc. Here’s its view on Nifty and Bank Nifty:Index view: NIFTYBenchmark indices snapped its three weeks winning streak and is trading with a downward bias during the current week…

Kotak Institutional Equities have a sell recommendation on Cochin Shipyard with the target price at Rs 860. Analysts said that the government has announced a Rs 70,000 crore package to boost domestic shipbuilding through capital support, legal reforms, and demand aggregation from oil & gas public sector units. This, coupled with CSL’s MoU with HD…

US President Donald Trump on Friday announced a 100% tariff on pharma products, along with 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks starting on October 1.The announcements came in a series of posts on his social media platform indicating that he remains committed to tariffs beyond…

MUMBAI: Standard Chartered India CEO P D Singh sees the India-Middle East trade corridor as a promising one for adoption of rupee invoicing, even though it’s a gradual shift. “It is picking up in Middle Eastern corridors and could expand in future, much like how Chinese yuan invoicing became common in solar equipment trade,” he…

NEW DELHI: A new study has estimated India’s logistics cost at 8% of GDP, with smaller firms having a higher burden.In 2023-24, for entities with turnover of up to Rs 5 crore, the cost added up to 16% of their output while it was pegged at 7.6% in the case of companies with turnover of…

BENGALURU: Accenture CEO Julie Sweet said H-1B visas are not a major concern for the company, noting that just 5% of its US workforce is on such visas.“This is really a non-issue because we only have about 5% of our people in the US on H-1B visas, and they’re for really specialised experience and skills…